710 related articles for article (PubMed ID: 30508136)
1. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
2. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
[TBL] [Abstract][Full Text] [Related]
7. Macrophage re-programming by JAK inhibitors relies on MAFB.
López-Navarro B; Simón-Fuentes M; Ríos I; Schiaffino MT; Sanchez A; Torres-Torresano M; Nieto-Valle A; Castrejón I; Puig-Kröger A
Cell Mol Life Sci; 2024 Mar; 81(1):152. PubMed ID: 38528207
[TBL] [Abstract][Full Text] [Related]
8. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
[TBL] [Abstract][Full Text] [Related]
9. Start RA treatment - Biologics or JAK-inhibitors?
Caporali R; Germinario S; Kacsándi D; Choy E; Szekanecz Z
Autoimmun Rev; 2024 Jan; 23(1):103429. PubMed ID: 37634678
[TBL] [Abstract][Full Text] [Related]
10. JAK1: Number one in the family; number one in inflammation?
Spinelli FR; Colbert RA; Gadina M
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii3-ii10. PubMed ID: 33950229
[TBL] [Abstract][Full Text] [Related]
11. Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Winthrop KL; Citera G; Gold D; Henrohn D; Connell CA; Shapiro AB; Shi H; Onofrei AM; Pappas DA; Schulze-Koops H
Ann Rheum Dis; 2021 Jan; 80(1):134-136. PubMed ID: 33046447
[No Abstract] [Full Text] [Related]
12. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
13. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
Dhir B; Meena SK; Sardana K; Sharath S
Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis.
Schäfer A; Kovacs MS; Eder A; Nigg A; Feuchtenberger M
Clin Rheumatol; 2022 Dec; 41(12):3707-3714. PubMed ID: 35965290
[TBL] [Abstract][Full Text] [Related]
15. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
Alduraibi FK; Singh JA
Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
[TBL] [Abstract][Full Text] [Related]
16. Jakpot! New small molecules in autoimmune and inflammatory diseases.
Ghoreschi K; Gadina M
Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
[TBL] [Abstract][Full Text] [Related]
17. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Sener S; Cam V; Ozen S; Batu ED
Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
[TBL] [Abstract][Full Text] [Related]
18. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea.
Kim YE; Kim YJ; Jeong DH; Kim S; Kim MJ; Kim HH; Jo KW; Park SH; Hong S
Semin Arthritis Rheum; 2024 Apr; 65():152362. PubMed ID: 38281468
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
Tanaka Y
Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi12-vi20. PubMed ID: 34951925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
